# Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

> **NCT07477366** · PHASE2 · NOT_YET_RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed B-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** CD19 t-haNK- IV Administration
- **DRUG:** N-803
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT07477366
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07477366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07477366, "Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07477366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*